Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05536804 · ClinicalTrials.gov registry record · Phase 2
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
A Phase 2 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT05536804: Active Phase 2 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
NCT05536804 is a Phase 2 study of Obesity and Type 2 Diabetes that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 140 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05536804, a Phase 2 study of Obesity and Type 2 Diabetes, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
Other
- Klinik Landstraße - Vienna
- Zentrum für klinische Studien Dr Hanusch Gmbh - Vienna
- Klinik Hietzing - Vienna
- LMC Clinical Research Inc. (Barrie) - Barrie
- LMC Clinical Research Inc. (Thornhill) - Concord
- Centre intégré universitaire de santé et de services sociaux de l'Estrie Centre Hospitalier Universitaire -T - Sherbrooke
- Toronto General Hospital - Toronto
- Fadia El Boreky Medicine - Waterloo
- Aarhus Universitetshospital, Skejby - Aarhus
- Centro de Investigación y Gastroenterología - Cuauhtémoc
Indiana
- American Health Network of Indiana, LLC - Avon - Avon
- American Health Network of Indiana, LLC - Greenfield - Greenfield
- Indiana University Health University Hospital - Indianapolis
- American Health Network of Indiana, LLC - Muncie - Muncie
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
- Kidney Associates of Colorado - Denver
Washington
- University of Washington Medical Center - Montlake - Seattle
- Providence Medical Research Center - Spokane - Spokane
California
- Valley Clinical Trials, Inc. - Northridge
Michigan
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division - Troy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2023-02-08 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What the registry record for NCT05536804 still lists
NCT05536804 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower).
The record links to 5 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05536804 names 20 study sites across 6 states, led by Other, Indiana, Colorado.
Frequently Asked Questions
What is clinical trial NCT05536804 about?
NCT05536804 is a clinical study titled "A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes". We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
What is the current status of trial NCT05536804?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2023-02-08. Estimated completion is 2026-10.
What conditions does trial NCT05536804 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight, Chronic Kidney Disease, T2D.
What interventions are being tested in trial NCT05536804?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT05536804?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05536804 being conducted?
This trial has 20 study locations across California, Colorado, Indiana, Michigan, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05536804's enrollment target sits among peer trials
140 401st of 1053 higher than 650 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI